Qualitek Labs guides for 35-40% revenue growth in FY27
The nano-cap lab-services company sets explicit FY27 targets in its MD&A, signaling confidence in its acquisition-led strategy after a year of strong execution.
— 2 earlier stories on Qualitek Labs Ltd. →What's new
- FY27 guidance: revenue growth 35-40%, EBITDA margin 25-27%, PAT margin 15-17%.
- Guidance supplements already-disclosed H2 FY26 and FY26 results.
- Nano-cap (₹434 cr) sets explicit targets, material for investor expectations.
Why it matters
For a nano-cap, explicit guidance of this granularity is rare and signals management confidence in its acquisition-led growth strategy. It moves Qualitek from a reported-history stock to a modelled-outlook stock, giving analysts and investors a concrete benchmark through FY27.
What we're watching
- Whether quarterly results align with the ambitious FY27 targets.
- Impact of acquisitions on margin expansion to guided 25-27% EBITDA.
- Any market reaction or analyst upgrades following the guidance.
The full read
Qualitek Labs has done something many nano-caps avoid: it gave explicit FY27 guidance. Revenue growth of 35-40%, EBITDA margins of 25-27%, and PAT margins of 15-17% are now on the table. The numbers supplement the already-disclosed FY26 results, which were known from prior filings, but the forward-looking targets are new. For a company with a market cap of ₹434 crore, this level of disclosure shifts the narrative from rearview reporting to forward accountability. The guidance suggests management expects the acquisition momentum and operational discipline to continue. The test will be whether quarterly results deliver against these targets. If they do, Qualitek could re-rate; if not, the stock may lose credibility. For now, the direction is clear.